AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 And Stimulate Collagen Through TNF-a Signaling

AGI Dermatics clinical research
indicates that the ability of bicyclic monoterpene diols (BMTds) to reduce
collagenese MMP-1 secretion and increase collagen production is dependent
on the TNF-a signaling in the fibroblasts. The data was presented at the
Poster Session at the 66th Annual Meeting of the American Academy of
Dermatology in San Antonio.

“Our prior research showed that BMTds increase collagen gene expression
and protein production while decreasing MMP-1 secretion,” said Daniel
Yarosh, PhD, President, AGI Dermatics. “This study gives us insight into
the cellular communication that allows BMTds to work so effectively and
efficiently in treating photodamaged skin.”

BMTds, a class of compounds known to increase nitric oxide levels, were
recently reported to play a major role in collagen synthesis. AGI
scientists questioned whether the transmission of BMTd factors were
influenced by the role of Interleukin-6 (IL-6) and TNF-A in regulating
collagen 1 and MMP-1 secretions.

In earlier studies of BMTds, AGI scientists observed a linear increase
in BMTd concentrations and secretion of interleukin-6 (IL-6), a
multi-functional cytokine that mediates a wide variety of functions in
cells, promotes cell proliferation and regulates gene expression. By
blocking the IL-6 signaling with a neutralizing IL-6 antibody, studies
showed a concomitant increase in MMP-1 and a reduction in collagen 1. The
effect of the neutralizing antibody, however, was gradually overcome by
increasing BMTd concentrations, indicating that IL-6 is not involved in the
transmission of the BMTd effect. Results indicated a linear decrease in
MMP-1 secretion and an increase in collagen production, two key components
in treatment of photoaged skin.

Similarly, blocking TNF-a signaling in the fibroblasts with a TNF-a
neutralizing antibody also increases MMP-1 and decreases collagen
secretion. However, blocking TNF-a signaling also blocks the BMTd effect.

AGI Dermatics is the developer of Remergent, a doctor-dispensed
skincare line based on the science of DNA repair. Pinoxide, an exclusive
and patented blend of bicyclic monoterpene diols, is formulated in
Remergent Microcirculation Therapy.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led
research of DNA repair of the skin for more than 20 years. Founded by
Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology,
dedicating research and development to DNA repair, solar impact on the
immune system, and cell- signaling in skin. The company’s application of
groundbreaking active ingredients and meticulously engineered liposome
delivery systems is validated in controlled clinical studies and published
in dozens of peer-reviewed scientific and medical journals.
agiderm

AGI Dermatics
agiderm

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.